ravelutamide

Ravelutamide (HC-1119) is an orally bioavailable, small molecule androgen receptor (AR) antagonist developed by Hinova Pharmaceuticals. It is a deuterated analog of the second-generation AR inhibitor enzalutamide, designed to enhance metabolic stability and potentially improve the safety and efficacy profile compared to its non-deuterated counterpart. Ravelutamide functions by competitively inhibiting the binding of androgens to the AR, thereby preventing the receptor's nuclear translocation and subsequent binding to DNA, which suppresses the growth of androgen-sensitive prostate cancer cells. The drug is primarily being evaluated for the treatment of metastatic castration-resistant prostate cancer (mCRPC), both as a monotherapy and in combination with other therapeutic strategies such as bipolar androgen therapy (BAT) and checkpoint inhibitors like camrelizumab.

Other names

deuterated enzalutamideravelutamide